Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

February 28, 2011

Study Completion Date

February 29, 2012

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Nexavar (Sorafenib) and irinotecan (Campto)

Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion

Trial Locations (5)

Unknown

Centre Oscar Lambret, Lille

Hopital Saint Eloi, Montpellier

Centre Rene Gauducheau, Nantes

Centre Antoine Lacassagne, Nice

CHU Robert Debre, Reims

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER